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Quantitative Antibiotic Use in Hospitals:
Comparison of Measurements, Literature Review,
and Recommendations for a Standard of Reporting
S. P. Kuster, C. Ruef, B. Ledergerber, A. Hintermann, C. Deplazes, L. Neuber, R. Weber
Abstract
Background: Reports on antibiotic use often lack complete
definitions of the units of measurement, hampering the
comparison of data between hospitals or hospital units.
Methods: To compare methods of measures of in-hospital
antimicrobial use, we determined aggregate in-hospital
consumption data at a tertiary care university hospital using
variations of nominators and denominators. Means of defined
daily doses (DDD) of individual antimicrobials per 100 bed-
days and per 100 admissions at each hospital and intensive
care unit (ICU) were calculated. Furthermore, a literature
review was performed for benchmarking purposes.
Results: Antibiotic use in different hospital units ranged
from 0.105 to 323.37 DDD/100 bed-days and from 4.23 to
6737.92 DDD/100 admissions, respectively. Including the
day of discharge in the denominator ‘bed-days’ underesti-
mated antibiotic use in various hospital wards by up to 27.7
DDD/100 bed-days (26.0%). Equating ‘numbers of patients
admitted to the hospital’ and ‘numbers of admissions’ on a
hospital level resulted in a difference of 192.6 DDD/100
admissions (64%) because patients transferred between
hospital units accounted for multiple admissions. Likewise,
reporting antimicrobial (Anatomical Therapeutic Chemical
[ATC] group ‘J’) instead of antibiotic (ATC group ‘J01’) use
led to a difference of 16.5 DDD/100 bed-days (19.3%). The
literature review revealed underreporting of complete defi-
nitions of antibiotic use measurements.
Conclusions: Data on in-hospital antimicrobial use vary
widely not only due to different antibiotic policies at dif-
ferent institutions but also due to different methods of
measures. Adherence to the standard of reporting the
methods of measurement is warranted for benchmarking
and promotion of rational antimicrobial use.
Infection 2008; 36: 549–559
DOI 10.1007/s15010-008-7462-z
Introduction
Antimicrobials are increasingly and often inappropriately
used in human and veterinary medicine and agriculture.
The quantity of antibiotic use in hospitals and the
community has been shown to correlate with antimicro-
bial resistance, resulting in increased morbidity, mortality,
and cost of health care [1–9]. The recommended standard
unit of measurement of antibiotic consumption for hos-
pitals is ‘defined daily dose (DDD) per 100 bed-days’, as
promoted by the World Health Organization (WHO)
[10]. The WHO assigned DDD is the assumed average
maintenance dose per day for a drug used for its main
indication in adults. Definitions of DDD are updated on a
yearly basis. Expressing antibiotic use by using the ‘DDD
per 100 bed-days’ unit is thought to allow hospitals to
compare their antibiotic use with other hospitals, regard-
less of differences in formulary composition, antibiotic
potency, and hospital census. Standardized comparisons
between organizations, aiming for improvement of oper-
ations, are often called benchmarking [11]. Benchmarking
can be defined as the process of comparing the perfor-
mance of an individual organization against a benchmark,
or ideal, level of performance. For hospital antibiotic use
data, benchmarks can be set across a sample of similar
organizations [12].
Even though the ATC/DDD system for all drugs was
available since the 1980s, it was not widely used or even
misunderstood, resulting in confusion due to publications
of antibiotic utilization data with only incomplete defini-
tions and without sufficient specification. Various other
measures of antibiotic use have subsequently been pro-
posed. The most common method is direct measurement of
the number of days of therapy (DOTs) [13, 14]. Advantages
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of measuring DOTs are lack of influence by changes in
the recommended DDD and by discrepancies between
the DDD and the preferred daily dose. Disadvantages
are its difficulty to measure without computerized
pharmacy records of individual patients. Other studies
use prescribed daily doses (PDDs), reflecting the usually
prescribed dose in adult hospitalized patients with
normal renal function [15]. When compared to DDDs,
PDDs might provide a better estimate of true antibiotic
use. However, large differences between DDD and PDD
of a substance that is used in large amounts may result
in substantial over- or underestimations not only of the
true use of that certain drug, but also of overall anti-
biotics [16]. The main disadvantage is its lack of stan-
dardization, as the usually prescribed daily dose of an
antibiotic may vary in different settings.
Not only the ATC/DDD system but also the
denominator ‘bed-days’ has been challenged. A clear
description of the methods used to calculate bed-days
(e.g., whether the days of admission and discharge count
together as one bed-day) is only provided rarely, and
additional terms such as occupied bed-days, census-days,
and patient-days are used frequently without precise
definitions [17]. Due to an increasing number of admis-
sions and a decreasing length of stay over the years,
numbers of ‘DDD per admissions’ may remain stable
while numbers of ‘DDD per 100 bed-days’ are rising [16].
Length of stay is of high importance for benchmark-
ing purposes. It correlates with age (older subjects have
longer lengths of stay), morbidity (severely ill patients
need longer hospitalization), and hospital size and hospi-
tal composition (length of stay varies depending on
medical specialty) [18, 19]. Due to economical and
insurance reasons, length of hospital stay varies substan-
tially between different countries and trends point toward
shorter length of hospital stay with intensified ambulatory
care worldwide [19–22].
We aimed to compare different measurements of
antibiotic use at our institution, to review the approaches
of analyses and presentation of hospital antibiotic use in
the literature for benchmark purposes, and to recommend
amendments to the standard of reporting the methods of
measurement. We determined antibiotic use in different
hospital wards of a tertiary care hospital using various
calculations of bed-days and admissions; analyzed con-
sumption data by including or excluding different antimi-
crobial classes; and studied the impact of changing DDD
definitions in the course of time on antibiotic use data.
Materials and Methods
Setting
The University Hospital Zurich is a 800-bed tertiary care
teaching hospital. It covers all specialties except pediatrics and
orthopedics. Six intensive care units are assigned to different
departments (Medical ICU; Cardiac Surgery ICU; Neurosurgery
ICU; Trauma ICU; Burn ICU, and Visceral, Thoracic, and
Transplant Surgery ICU). Bone marrow and solid organ trans-
plantations are performed in specialized units.
Data Collection
Aggregate in-hospital antimicrobial use data, including both
deliveries and returns, for 2006 were collected from the hospital
pharmacy and entered into a Microsoft Office Access 2003
database similar to the ABC Calc developed by the Danish
Statens Serum Institut [23]. Bed-days and numbers of admissions
were calculated from computerized hospital administration
records of each patient hospitalized for ‡ 24 h in the same hos-
pital site, service, and defined patient care areas counting the
days of admission and discharge together as one bed-day unless
specified otherwise. Length of stay is calculated as numbers of
bed-days divided by numbers of patients admitted. As one
patient can be admitted several times during one hospitalization
due to transfers between wards, the number of admissions is
larger than the numbers of patients admitted. Means of DDD
divided by 100 bed-days and by 100 admissions were calculated
measuring means of each hospital site. Unless indicated other-
wise, the 2007 version (Group ‘J01’ [Antibiotics for systemic
use]) of the ‘WHO Guidelines for ATC (Anatomical Therapeutic
Chemical classification index for antibiotics) classification and
DDD assignment’ was used. Alterations in definitions of DDD
of the past years were retrieved from the WHO website [10].
Definitions
‘Antibiotics’ are all substances of ATC group ‘J01’ (Antibiotics for
systemic use). ‘Antimicrobials’ are all substances of ATC group ‘J’
(anti-infectives for systemic use, including antibiotics for systemic
use, antimycotics for systemic use, antimycobacterials, antivirals for
systemic use, immune sera, and immunoglobulins and vaccines)
[10]. Antiparasitic products (antiprotozoals, antihelminthics, and
ectoparasiticides) are assigned to ATC group ‘P’ and are thus not
included.
Literature Review
For benchmarking purposes, a literature review of reports on
hospital antibiotic use applying the ATC/DDD system was
conducted. The period of January 2000 until January 2008 was
covered using MEDLINE (combining the MeSH search terms
‘anti-infective agents’ and ‘hospital’) and PubMed (search terms
used alone and in combination included ‘antimicrobial’, ‘antibi-
otic’, ‘DDD’, ‘methodology’ and ‘hospital’). The reference lists
of each publication were reviewed to identify additional reports
on hospital antibiotic use.
Results
Overall Antibiotic Use at University Hospital Zurich
In 2006, 239,314 bed-days were recorded and 33,576 pa-
tients were admitted to our hospital, accounting for a total
of 55,102 admissions (including transfers between units)
and a mean length of stay of 7.13 days (day of hospital
admission and of discharge counted as one day). Mean
antibiotic use (all wards, ATC group ‘J01’) was 69.15
DDD/100 bed-days and 300.34 DDD/100 admissions,
respectively. Mean antimicrobial use (ATC group ‘J’) was
85.69 DDD/100 bed-days (372.14 DDD/100 admissions) in
the entire hospital and 125.88 DDD/100 bed-days (451.80
DDD/100 admissions) in the intensive care units. Includ-
S.P. Kuster et al. Measurements of Antibiotic Use in Hospitals
550 Infection 36 Æ 2008 Æ No. 6  URBAN & VOGEL
ing or excluding Intensive Care Units in aggregate anti-
biotic use data results in a difference of 7.65 DDD/100
bed-days (12.4%) (Table 1). Including the Bone Marrow
Transplant Unit in the aggregated ICU data results in a
further increase of 21.14 DDD/100 bed-days (16.8%).
Antibiotic Use in Various Hospital Wards
Antibiotic use varied markedly between different spe-
cialties or hospital wards (Table 1). The Bone Marrow
Transplant Unit represented the site with the highest
antibiotic use (323.37 DDD/100 bed-days or 6,737.92
DDD/100 admissions). However, 150.34 DDD/100 bed-
days thereof consisted of gentamicin, an antibiotic with a
remarkable difference between DDD (240 mg) and pre-
scribed daily dose, provided that a once daily dosing
regimen is used (5 mg/kg body weight once daily). If the
Defined Daily Dose was adapted to this prescribed daily
dose (350 mg for a person weighing 70 kg), gentamicin
use would decrease from 150.34 to 103.09 DDD/100 bed-
days. Depending on specialty, considerable differences
within Intensive Care Units (ICUs) (101.16 DDD/100
bed-days or 351.19 DDD/100 admissions in Cardiac Sur-
gical ICU compared to 176.09 DDD/100 bed-days or
727.58 DDD/100 admissions in Visceral, Thoracic and
Transplant Surgical ICU) were observed.
Differences Depending on the Definition
of the Denominator
Bed-days. Due to differences in the definition of the
denominator ‘bed-days’, discrepancies of up to 26.0%
were found for DDD/100 bed-days, depending on whether
the days of admission and discharge were counted as one
bed-day or as two bed-days (Table 2). A short length of
stay resulted in a larger difference, playing a key role
when reporting ICU antibiotic use data.
Admissions. In contrast, ‘DDD/100 admissions’ is
thought to be a measure which is less influenced by length
of stay and more likely to correlate with the risk for
antimicrobial resistance. ‘DDD/100 bed-days’ and ‘DDD/
100 admissions’ are contrasted in Table 1 and Figure 1.
However, as observed in the Bone Marrow Transplant
Unit, in wards with a long mean length of stay and a high
antibiotic use (often in combination therapy), antibiotic
use density measured in the DDD/100 admissions format
is more likely to take extreme values. Due to transfers
between wards, patients may be admitted several times
during their hospital stay. Therefore, 33,576 patients who
were admitted to our hospital accounted for a total of
55,102 admissions to different hospital units. Not defining
the denominator ‘admissions’ precisely may bias the re-
sults substantially.
Differences Depending on the Definition
of the Numerator
DDD definitions. Since 2000, definitions of DDD of 11
substances of group ‘J01’ of the ‘WHO Guidelines for
ATC classification and DDD assignment’ have been
changed [10]. Three of these substances (amoxicillin and
enzyme inhibitor, cefuroxime and cefepime) were found
among the five most widely used antibiotics at the Uni-
Table 1
Differences in DDD/100 bed-days and DDD/100 admissions of different wards at a tertiary care university hospital in 2006.
Wards included in analysis DDD/100 bed-days DDD/100 admissions
All wards, including intensive care units and Bone Marrow Transplant Unit 69.15 300.34
All wards, excluding intensive care units and Bone Marrow Transplant Unit 61.50 283.17
All intensive care units, including Bone Marrow Transplant Unit 147.02 578.95
All intensive care units, excluding Bone Marrow Transplant Unit 125.88 451.80
Bone Marrow Transplant Unit 323.37 6,737.92
ICU - visceral, thoracic and transplant surgery 176.09 727.58
ICU - internal medicine 150.90 534.04
ICU - trauma 126.42 530.00
ICU - burns 106.63 610.71
ICU - neurosurgery 106.62 304.18
ICU - cardiac surgery 101.16 351.19
Internal medicine (including oncology) 110.40 559.70
Urology 95.29 343.45
Ophthalmology and ear-nose-throat 68.06 200.60
Surgery 64.32 278.09
Neurosurgery 54.33 232.28
Dermatology 38.41 264.72
Radio-oncology 33.20 258.24
Neurology 28.72 126.58
Gynecology and obstetrics 22.52 90.95
Rheumatology 20.96 241.62
Psychiatry 0.10 4.23
DDD: defined daily dose; ICU: intensive care unit
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versity Hospital Zurich in 2006. The DDD of amoxicillin
and enzyme inhibitor was changed from 1 g (parenteral)
to 3 g (parenteral) in 2005, the DDD of levofloxacin from
0.25 g (oral and parenteral) to 0.5 g (oral and parenteral)
in 2004, the DDD of cefuroxime from 1 g (oral)/4 g
(parenteral) to 0.5 g (oral)/3 g (parenteral), the DDD of
ceftazidime from 6 g (parenteral) to 4 g (parenteral) and
the DDD of cefepime from 4 g (parenteral) to 2 g (par-
enteral), all in 2000. Applying the 2007 version of the
‘WHO Guidelines for ATC classification and DDD
assignment’ instead of the 2002 version resulted in a
reduction of overall antibiotic use of 20.6% at our hospital
(69.15 DDD/100 bed-days [2007 version] vs 87.09 DDD/
100 bed-days [2002 version]), mainly due to the altered
DDD of amoxicillin and enzyme inhibitor.
Drug classes. These included antimicrobials (ATC
group ‘J’) other than antibiotics (ATC group ‘J01’) ac-
count for 16.5 DDD/100 bed-days (19.25%) in the entire
hospital and for 30.6 DDD/100 bed-days (19.5%) in the
Intensive Care Units, respectively. Differences on hospital
site level are shown in Table 3.
Benchmarking
A comparison of antibiotic use data originating from
various countries is shown in table 4. Several difficulties
with benchmarking were noted. Many studies do not
provide essential methodological information. A large
proportion of the publications lack a clear definition of the
Table 2
Differences in DDD/100 bed-days of different wards depending on the definition of the denominator.
Hospital ward Mean length of stay
excluding day of
discharge (days)
Antibiotic use
excluding day
of discharge
(DDD/100 bed-days)
Antibiotic use including
day of discharge
(DDD/100 bed-days)
Difference (%)
ICU - neurosurgery 3.85 106.616 78.945 26.0
Ophthalmology and ear–nose–throat 3.95 68.057 50.817 25.3
ICU - cardiac surgery 4.47 101.164 78.540 22.4
ICU - internal medicine 4.54 150.896 117.652 22.0
Urology 4.60 95.292 74.595 21.7
Gynecology and obstetrics 5.04 22.524 18.053 19.8
ICU - visceral, thoracic and
transplant surgery
5.13 176.088 141.776 19.5
ICU - trauma 5.19 126.423 102.075 19.3
Neurosurgery 5.28 54.329 44.030 19.0
Surgery 5.32 64.317 52.236 18.8
Neurology 5.41 28.716 23.406 18.5
Internal medicine
(including oncology)
6.07 110.400 92.210 16.5
ICU - burns 6.73 106.627 90.778 14.9
Dermatology 7.89 38.407 33.540 12.7
Radio-oncology 8.78 33.202 29.420 11.4
Rheumatology 12.53 20.963 19.290 8.0
Bone Marrow Transplant Unit 21.84 323.373 308.564 4.6
Psychiatry 41.41 0.105 0.102 2.4
All wards 7.13 69.15 56.21 18.7
Mean length of stay includes only patients hospitalized > 24 h; ‘Antibiotics’ are all substances of ATC group ‘J01 (Antibiotics for systemic use);
DDD: defined daily dose; ICU: intensive care unit
Figure 1. Comparison of antibiotic use (ATC group ‘J01’) between
different wards of the University Hospital Zurich presented in ‘DDD/
100 bed-days’ and ‘DDD/100 admissions’. Abbreviations: DDD:
defined daily dose; ICU: intensive care unit; ATC: anatomical
therapeutic chemical classification index for antibiotics; ‘Antibiotics’
are all substances of ATC group ‘J01 (antibiotics for systemic use)’.
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drugs according to the Anatomical Therapeutic Chemical
classification index for antibiotics whereas some do indeed
provide a complete list of all antimicrobials including
DDD definitions. The version of the ‘WHO Guidelines
for ATC classification and DDD assignment’ used is often
but not always mentioned. A definition of the term ‘bed-
day’ is only provided in four studies, all originating from
The Netherlands or from Sweden. A discrimination of
different wards or intensive care units is rarely provided
as well as a discrimination of the hospital affiliation
(e.g., primary vs secondary vs tertiary care hospital) where
data from multiple hospitals are presented. Additionally,
different versions of the ‘WHO guidelines for ATC clas-
sification and DDD assignment’ are used in varying
studies.
Discussion
In-hospital antimicrobial use varies widely, which may
partially be explained by differences in patients’ and
hospital characteristics, antibiotic policies, physicians’
education, or health care systems. However, a substantial
part of the differences may be the result of differences in
methods to measure antimicrobial use. Exploiting original
data collected in 2006 at a university-based tertiary care
hospital, we demonstrate how different definitions of
nominators and denominators lead to substantially dif-
ferent results. This effect renders valid benchmarking
difficult. Consequently, we propose an improved format
for reporting hospital antibiotic use.
We demonstrate that hospital structure is an impor-
tant determinant for antibiotic use and should accurately
be disclosed. The definition of the denominator ‘bed-day’
has been identified as a major obstacle to meaningful data
comparison. Due to the lack of a precise definition, sub-
stantial discrepancies can result especially on wards with a
short mean length of stay. We propose to count the days
of admission and discharge together as one bed-day,
especially when data on hospital site level are collected, to
avoid duplicate counts when patients are transferred from
one clinical unit to another. Not only for data comparison
within a single institution, but even more important for
studies involving multiple centers, a uniform denominator
seems mandatory.
Antibiotic use calculated per admissions or per bed-
days complement one another. DDD/100 bed-days may
more appropriately reflect days of therapy and DDD/100
admissions may provide a better estimate of antibiotic
selection pressure, although studies to prove this assump-
tion are lacking [42]. Both calculations are easily available
in contrast to data on prescription in individual patients.
Trends in antibiotic use over time have been shown
to differ when both measures are contrasted [16, 42].
Therefore, both measures should be reported when
patient-level data are not available. But, also the denom-
Table 3
Differences in DDD/100 bed-days of different wards depending on the definition of the numerator.
Hospital ward Antibiotics
(ATC group ‘J01’)
(DDD/100 bed-days)
Antimicrobials
(ATC group ‘J’)
(DDD/100 bed-days)
Difference (%)
Internal medicine 110.40 156.60 29.5
ICU - visceral, thoracic and
transplant surgery
176.09 246.77 28.6
ICU - internal medicine 150.90 209.53 28.0
Bone Marrow Transplant Unit 323.37 438.25 26.2
ICU - cardiac surgery 101.16 126.84 20.2
Psychiatry 0.10 0.13 20.0
Rheumatology 20.96 25.97 19.3
Surgery 64.32 75.78 15.1
Neurology 28.72 32.75 12.3
Neurosurgery 54.33 61.26 11.3
Dermatology 38.41 43.30 11.3
ICU - neurosurgery 106.62 119.30 10.6
ICU - burns 106.63 118.15 9.7
ICU - trauma 126.42 138.43 8.7
Radio-oncology 33.20 36.22 8.3
Urology 95.29 100.37 5.1
Gynecology and obstetrics 22.52 23.65 4.7
Ophthalmology and ear–nose–throat 68.06 70.67 3.7
All wards 69.15 85.69 19.3
Antibiotics are all substances of ATC group ‘J01’ (antibiotics for systemic use); Antimicrobials are all substances of ATC group ‘J’ (anti-
infectives for systemic use, including antibiotics for systemic use, antimycotics for systemic use, antimycobacterials, antivirals for systemic
use, immune sera and immunoglobulins and vaccines); DDD: defined daily dose; ATC: anatomical therapeutic chemical classification index for
antibiotics; ICU: intensive care unit
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inator ‘admissions’ must be defined properly. ‘Numbers of
patients admitted to the hospital’ cannot be equated to
‘numbers of admissions’ because patients transferred
between hospital units account for multiple admissions.
Several aspects concerning the numerator have to be
taken into account when reporting antibiotic use data.
Due to recent changes in the definitions of DDD of
substances that are widely used (e.g., amoxicillin with
enzyme inhibitor and levofloxacin) in hospitals, the ver-
sion of the ‘WHO Guidelines for ATC classification and
DDD assignment’ used plays an important role in
benchmarking. This must be taken into account for lon-
gitudinal comparisons. The Anatomical Therapeutic
Chemical Classification Index for antibiotics offers the
advantage to clearly define the drug classes that are in-
cluded in a study. Not defining the drugs included in a
survey, using arbitrary drug selections or other definitions
(e.g., providing a list of drugs included) further impedes
benchmarking.
Aggregate antibiotic use of our hospital is comparable
to published data originating from Europe, the United
States, and Asia [6, 13, 15–17, 24–51]. However, differ-
ences in methodology limit the comparability of the re-
sults of the various studies. We particularly observed large
discrepancies between the DDD of gentamicin and the
usually prescribed dose in daily practice in the Bone
Marrow Transplant Unit resulting in a systematic bias.
Strengths of our study are the comprehensive data set
of DDD/100 bed-days and DDD/100 admissions from all
wards of an entire university hospital, providing a basis for
future interventions to promote rational antimicrobial
use, and for further research on development and spread
of antimicrobial resistance within our institution. Previous
studies mainly focused on areas with high antibiotic
use, e.g., hemato-oncology or intensive care units [6, 17,
33, 52]. Reporting data from all patient care areas, how-
ever, permits to unmask unexpected patterns and time-
trends within individual hospital units [31, 37, 53].
Furthermore, we quantified the impact of different
methodological issues that are often incompletely re-
ported in the present literature [54].
The findings of our study are limited to a large ter-
tiary care hospital. Our data show that differences be-
tween units of measurement are largest between ICUs
and specialized units. It remains unclear whether different
units of measurements would have the same impact on a
smaller peripheral hospital. Other limitations are that we
could not discriminate antimicrobial use among specialties
of internal medicine (e.g., infectious diseases, oncology,
and hemato-oncology) or surgery (e.g., traumatology,
visceral surgery, and thoracic surgery) due to hospital and
department structures. Future changes in hospital service
structure may limit comparability of data and measure-
ment of trends over time. The study of the relation be-
tween antimicrobial use and resistance would require data
collection on the level of individual patients, e.g., through
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retrieving data from applications for electronic drug pre-
scribing [55]. Nevertheless, the use of aggregate data
provided by the hospital pharmacy is a common method,
because, as it is the case in our institution, prescription
data on the individual patient level often are not acces-
sible.
The recently published ‘Guidelines for Developing an
Institutional Program to Enhance Antimicrobial Stew-
ardship’ from the Infectious Disease Society of America
and the Society for Healthcare Epidemiology of America
recommend using the ATC/DDD system without elabo-
rating the difficulties of this method in detail [56]. On the
basis of our data, we provide more distinct and practical
recommendations to circumvent the pitfalls that may
emerge when using aggregate hospital antibiotic use data.
In conclusion, methodological details are a pre-
requisite in publications on antibiotic use to provide a
basis for benchmarking of hospitals and individual hos-
pital units. To counteract the publication of utilization
studies with incomplete definitions and without sufficient
specifications in medical journals, researchers should be
forced to precisely report hospital composition and affil-
iation, wards included in the analysis, a clear definition of
the terms ‘bed-day’, and ‘admissions’, the version of the
WHO Guidelines for ATC classification and DDD
assignment used and the drugs that were included in their
publications (Table 5). Ongoing and open-access publi-
cations of hospital antibiotic use data are crucial for
quality control, prevention of nosocomial infections, and
the struggle against the worldwide emergence of antibiotic
resistance.
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